Animal models in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 26, Issue 5, 2008, Pages 941-946

  Rogai, Veronica ^a   Lories, Rik J ^b   Guiducci, Serena ^a   Luyten, Frank P ^b   Cerinic, Marco Matucci ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Laboratory for Skeletal Development and Joint Disorders   (Belgium)

Author keywords

Animal models; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; BLEOMYCIN; CARRIER PROTEIN; CD19 ANTIBODY; COLLAGEN TYPE 1; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBRILLIN 1; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN TSK1; PROTEIN TSK2; RAG2 PROTEIN; RANTES; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL MODEL; BAGG ALBINO MOUSE; C3H MOUSE; C57BL 10 MOUSE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKEN; CHROMOSOME 2; DBA 2 MOUSE; DISEASE MODEL; DRUG INDUCED DISEASE; EMPHYSEMA; FIBROSIS; GENE MUTATION; GENE OVEREXPRESSION; GRAFT VERSUS HOST REACTION; HETEROZYGOSITY; KNOCKOUT MOUSE; LUNG FIBROSIS; MOUSE STRAIN; MOUSE STRAIN LPJ; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS;

ANIMALS; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; MICE; MICE, TRANSGENIC; SCLERODERMA, SYSTEMIC; TRANSPLANTATION;

EID: 57249111623     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. LEROY J et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
2. GREEN MC, SWEET HO, BUNKER LE: Tightskin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976; 82: 493-512.
3. SIRACUSA LD, MCGRATH R, MA Q et al.: A tandem duplication within the fibrillin-1 gene is associated with the mouse tight skin mutation. Genome Res 1996; 6: 300: 31-6.
4. PABLOS JL, EVEREAT ET, NORRIS JS: The tight skin mouse: an animal model of systemic sclerosis. Clin Exp Rheumatol 2004; 22 (Suppl. 33): 81-5.
5. JIMENEZ SA, MILLANA, BASHEY RI: Scleroderma-like alterations in collagen metabolism occurring in the Tsk (tight skin) mouse. Arthritis Rheum 1984; 27:180-5.
6. BONA CA, MURAI C, CASARES S et al.: Structure of the mutant fibrillin-1 gene in the tight skin (Tsk) mouse. DNA Res 1997; 4: 267-71.
7. CHATTERJEE S, MARK ME, WOOLEY PH, LAWRENCE WD, MAYES MD: Increased dermal elastic fibers in the tight skin mouse. Clin Exp Rheumatol 2004; 22: 617-20.
8. SAITO S, NISHIMURA H, BRAMEANU TD et al.: Characterization of mutated protein encoded by partially duplicated fibrillin-1 gene in tight skin (Tsk) mice. Mol Immunol 1999; 36: 169-76.
9. LEMAIRE M, FARINA G, KISSIN E et al.: Mutant fibrillin 1 tight skin mice increased extracellular matrix incorporation of micro fibril-associated glycoprotein 2 and type I collagen. Arthritis Rheum 2004; 50: 915-26.
10. VOON H, LOWRI A, EVANS et al.: Monocyte Chemoattractant Protein 3 as a Mediator of Fibrosis; Arthritis Rheum 2003; 48: 1979-91.
11. YANABA K, KOMURA K, KODERA M et al.: Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 2006; 65: 124-6.
12. ONG CJ, IP S, TEH SJ et al.: A role of T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999; 196: 60-8.
13. ONG C, WONG C, ROBERTS CR et al.: Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28: 2619-29.
14. KODERA T, MCGAHA TL, PHELPS R et al.: Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-[beta] production by fibroblasts. Proc Natl Acad Sci USA 2002; 99: 3800-5.
15. MCGAHA T, SAITO S, PHELPS RG et al.: Lack of skin fibrosis in tight skin (Tsk) mice with targeted mutation in the interleukin-4R-α and transforming growth factor-β genes. J Invest Dermatol 2001; 116: 136-43.
16. BOCCHIERI MH, HENRIKSEN PD, KASTURI KN et al.: Evidence for autoimmunity in the tight skin (Tsk/+) mouse model of progressive systemic sclerosis. Arthritis Rheum 1991; 34: 599-605.
17. MURYOI T, KASTURI KN, KAFINA MJ et al.: Self reactive repertoire of tight skin mouse: Immunochemical and molecular characterization of anti-topoisomerase I autoantibodies. Autoimmunity 1991; 9: 109-17.
18. SHIBATA S, MURYOI T, SAITOH Y et al.: Immunochemical and molecular characterization of anti-RNA polymerase I autoantibodies produced by tight skin mouse. J Clin Invest 1993; 92: 984-92.
19. SAITO E, FUJIMOTO M, HASEGAWA M et al.: CD19-dependent B lymphoctyte signalling thresholds influence skin fibrosis and autoiimunity in the thight skin mice. J Clin Invest 2002; 109: 1453-62.
20. PHELPS RG, DAIAN C, SHIBATA S et al.: Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun 1993; 6: 701-18.
21. CHRISTNER PJ, PETERS J, HAWKINS D et al.: The tight skin 2 mouse: an animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 1995; 38: 1791-8.
22. CHRISTNER PJ, HITRAYA EG, PETERS J, MCGRATH R, JIMENEZ SA: Transcriptional activation of the α (I) procollagen gene and upregulation of the α(I) and α1(III) collagen mRNA's in tight skin 2 (Tsk2) dermal fibroblasts. Arthritis Rheum 1998; 41: 2132-42.
23. LEROY EC: In WYNGAARDEN JB, SMITH LH, BENNETT JC/Eds.) Cecil Textbook of Medicine, W.B. Saunders, Philadelphia 1992; 530.
24. KÄHÄRI V, VUORIO T, NANTO-SALONEN K, VUORIO E: Increased type I collagen mRNA levels in cultured scleroderma fibroblasts. Biochim Biophys Acta 1984; 781: 183-6.
25. JIMENEZ SA, FELDMAN G, BASHEY RI, BIENKOWSKI R, ROSENBLOOM J: Coordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J 1986; 237: 837-43.
26. KÄHÄRI V-M, MULTIMAKI P, VUORIO E: Elevated pro α2(I) collagen mRNA levels in cultured scleroderma fibroblasts result from an increased transcription rate of the corresponding gene. FEBS Lett 1987; 215: 331-4.
27. GARDNER H, BROBERG A, POZZ1 A et al.: Absence of integrin alpha1beta in the mouse causes loss of feedback regulation of collagen synthesis in normal and wounded dermis. J Cell Sci 1999; 112: 263-72.
28. JIMENEZ SA, CHRISTNER P: Animal models of systemic sclerosis. Clin Dermatol 1994; 12: 425-36.
29. STASTNY P, STEMBRIDGE VA, ZIFF M: Homologous disease in the adult rat, a model for autoimmune disease, i. general features and cutaneous lesions. J Exp Med 1963; 118: 635-48.
30. CLAMAN HN, JAFFEE BD, HUFF JC, CLARK RA: Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 1985; 94: 73-84.
31. LAKOS G, TAKAGAWA S, VARGA J: Animal models of scleroderma. Methods Mol Med 2004; 102: 377-39.
32. ZHANG Y, GILLIAM A: AnimaA models for scleroderma: an update. Curr Rheumatol Rep 2002; 4: 150-62.
33. ZHANG Y, MCCORMICK LL, DESAI SR et al.: Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002; 168: 3088-98.
34. MCCORMICK LL, ZHANG Y, TOOTELL E, GILLIAM AC: Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human sclerodermia. J Immunology 1999; 163: 5693-9.
35. ZHANG Y, MCCORMICK LL, DESAI SR et al.: Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002; 168: 3088-98.
36. CHARLEY MR, BANGERT JL, HAMILTON BL et al.: Murine graft-versus-host skin disease: A chronologic and quantitative analysis of two histologic patterns. J invest Dermatol 1983; 81: 412-7.
37. RUZEK MC, JHA S, LEDBETTER S et al.: A modifed model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004; 50: 1319-31.
38. LAZO AS, HOYT DG, SEBTI SM, PITT BR: Bleomicyn: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol Ther 1990; 47: 347-58.
39. YAMAMOTO T, TAKAGAWA S, KATAYAMA I et al.: Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: Implications for the treatment of systemic sclerosis. J Invest Dermatol 1999; 112: 456-62.
40. YAMAMOTO T, TAKAGAWA S, KATAYAMA I et al.: Animal Model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
41. YAMAMOTO T, TAKAGAWA S, KATAYAMA I et al.: Animal Model of sclerotic skin. II: Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/WV mice. J Rheumatol 1999; 26: 2628-34.
42. YAMAMOTO T, KURODA M, NISHIOKA K: Animal model of sclerotic skin. III: histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292: 535-41.
43. YAMAMOTO T, NISHIOKA K: AnimalImodel of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001; 117: 999-1001.
44. YAMAMOTO T, NISHIOKA K: Animal model of sclerotic skin. V: Increased expression of α-smooth muscle actin in fibroblastic cells in bleomycin-induced cleroderma. Clin Immunol 2002; 102: 77-83.
45. YAMAMOTO T, NISHIOKA K: Animal model of sclerotic skin.VI: Evaluation of bleomycin-induced skin sclerosis in nude mice. Arch Dermatol Res 2004; 295: 453-6.
46. KOVASC EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 1999; 20: 307-12.
47. NISHIOKA K, KOBAYASHI Y, KATAYAMA I, TAKIJIRI C: Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987; 123: 205-8.
48. LEROY EC, SMITH EA, KAHALEH MB, TROJANOWSKA M, SILVER RM: A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor the answer? Arthritis Rheum 1989; 32: 817-25.
49. OI M, YAMAMOTO T, NISHIOKA K: Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-"susceptible" mouse strains. J Med Dent Sci 2004; 51: 7-17.
50. TAKAGAWA S, LAKOS G, MORI Y et al.: Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003; 121: B41-50.
51. DISTLER O, PAP T, KOWAL-BIELECKA O et al.: Overexpresion of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001; 44: 2665-78.
52. SAMBO P, JANNINO L, CANDELA M et al.: Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999; 112: 78-84.
53. GERSHWIN ME, ABPLANALP HA, CASTLES JJ et al.: Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma). J Exp Med 1981; 153: 1640-59.
54. WICK G, SGONC R, KROEMER G: Autoimmune disease, spontaneous animal models. In DELVES PJ, ROITT IM (Eds.) Encyclopedia of Immunology. Academic Press, London, 1998; 280-7.
55. GRUSCHWITZ MS, MOORMAN S, KRÖMER R et al.: Analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmun 1988; 4: 577-93.
56. AUSSERLECHNER MJ, SGONC R, DIETRICH H, WICK G: Altered procollagen mRNA expression during the progression of avian scleroderma. Mol Med 1997; 3: 654-62.
57. BLACK CM: The aetiopathogenesis of systemic sclerosis. J Int Med 1993; 234: 3-8.
58. CLAMAN HN: On scleroderma. Mast cells, endothelial cells, and fibroblasts. JAMA 1989; 262: 1206-9.
59. BLACK CM: Systemic sclerosis (scleroderma). Introduction. Ann Rheum Dis 1991; Nov, 50 (Suppl. 4): 837-8.
60. VAN DE WATER J, GERSHWIN ME, ABPLANALP H, WICK G and VON DER MARK K: Serial observations and definition of mononuclear cell infiltrates in avian scleroderma, an inherited fibrotic disease of chickens. Arthritis Rheum 1984; 27: 807-15.
61. WILSON TJ, VAN DE WATER J, MOHR FC et al.: Avian scleroderma: Evidence for qualitative and quantitative T cell defects. J Autoimmun 1992; 5: 261-76.
62. HAYNES DC and GERSHWIN ME: Diversity of autoantibodies in avian scleroderma an inherited fibrotic disease of white leghorn chickens. J Clin Invest 1984; 73: 1557-68.
63. GRUSCHWITZ MS, SHOENFELD Y, KRUPP M, GERSHWIN ME, PENNER E, BREZINSCHEK HP and WICK G: Antinuclear antibody profile in UCA line 200 chickens: a model for progressive systemic sclerosis. Int Arch Allergy Immunol 1993; 100: 307-13.